Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002049 · ClinicalTrials.gov registry record · NA

Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

A NA study of HIV Infections, sponsored by Immunobiology Research Institute.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002049: Completed NA study of HIV Infections, sponsored by Immunobiology Research Institute.

NCT00002049 is a NA study of HIV Infections that has completed, run by Immunobiology Research Institute. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002049, a NA study of HIV Infections, has completed, sponsored by Immunobiology Research Institute.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings of patients infected with HIV who do not yet have AIDS.

Conditions Studied

HIV Infections

Interventions

  • DRUG Thymopentin

Study Locations (1)

New Jersey

  • Immunobiology Research Institute - Annandale

Trial Details

FieldValue
Phase NA
Immunobiology Research Institute

7 total trials

What the finished NCT00002049 record still lists

NCT00002049 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Thymopentin is the first listed.

NCT00002049 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002049 about?

NCT00002049 is a clinical study titled "Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients". Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings of patients infected with HIV who do not yet have AIDS.

What is the current status of trial NCT00002049?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002049 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002049?

The interventions under investigation include: Thymopentin (DRUG).

Who is sponsoring clinical trial NCT00002049?

This trial is sponsored by Immunobiology Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002049 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002049, the US trial registry maintained by the National Library of Medicine. NCT00002049 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.